Huangshan Tianmu Mint Pharmaceutical
subsidiary of the listed Tianmu Pharmaceutical group; received a renewed drug-manufacturing license from the Anhui Provincial Drug Administration (valid through December 31, 2030) covering raw-material-drug production of menthol and mint-sucrose oil.
- Country
- China
Anhui NMPA drug manufacturing license renewed to 2030
cn
Coverage
| CN | EU | |
|---|---|---|
| specialty-fine-chem | ✓ | ✓ |
Regulatorsreachnmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic menthol | specialty-fine-chem | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.